brontictuzumab   Click here for help

GtoPdb Ligand ID: 11361

Synonyms: OMP-52M51 | OMP52M51
Compound class: Antibody
Comment: Brontictuzumab (OMP-52M51) is a fully human anti-NOTCH1 monoclonal antibody [4-5]. It was developed by OncoMed Pharmaceuticals. Peptide sequence analysis reveals that the heavy and light chains that make up brontictuzumab are claimed in Oncomed patent US20140011271A1 [3]. The heavy chain is SEQ ID NO:22 (52M51-H4), and the light chain is SEQ ID NO:26 (2M51L3), making the brontictuzumab structure 52M51H4L3.
Click here for help
1. Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P. (2018)
A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
Ann Oncol, 29 (7): 1561-1568. [PMID:29726923]
2. Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William Jr WN, Glisson BS, Wick MJ et al.. (2017)
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
J Clin Oncol, 35 (3): 352-360. [PMID:27870570]
3. Gurney Al, Hoey TC, Bruhns MF, Axelrod FT. (2014)
Notch1 receptor binding agents and methods of use thereof.
Patent number: US20140011271A1. Assignee: Oncomed Pharmaceuticals. Priority date: 08/07/2008. Publication date: 09/01/2014.
4. López-Guerra M, Xargay-Torrent S, Fuentes P, Roldán J, González-Farré B, Rosich L, Silkenstedt E, García-León MJ, Lee-Vergés E, Giménez N et al.. (2020)
Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells.
Oncogene, 39 (6): 1185-1197. [PMID:31616059]
5. Silkenstedt E, Arenas F, Colom-Sanmartí B, Xargay-Torrent S, Higashi M, Giró A, Rodriguez V, Fuentes P, Aulitzky WE, van der Kuip H et al.. (2019)
Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
J Exp Clin Cancer Res, 38 (1): 446. [PMID:31676012]